AZD5305 |
AZD5305 : Inhibitor of PARP1
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| PARP1 |
|
|
Inhibitor
100 nM
Selectivity
In Vitro Selectivity Assessment
Selectivity Assessment Description:
PARP Family Proteomic Data demonstrate that AZD5305 is highly selective for PARP1 over the other mem ...
Potency Cellular
In Vitro
PARP1
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.1c01012
In Vivo Validations
Mouse
Dose: 10, 1, 0.1, and 0.03 mg/kg
Route of delivery:
Oral
Plasma half life:
8 h
Systemic clearance:
0.23 mL/min/kg
Fb :
99.927%
Bioavailability:
77%
Volume of Distribution at Steady-State:
0.17 L/Kg
DOI Reference: 10.1021/acs.jmedchem.1c01012
Rat
Dose: 10, 1, 0.1, and 0.03 mg/kg
Route of delivery:
Oral
Plasma half life:
4.6 h
Systemic clearance:
1.1 mL/min/kg
Fb :
99.968%
Bioavailability:
132%
Volume of Distribution at Steady-State:
0.38 L/Kg
DOI Reference: 10.1021/acs.jmedchem.1c01012
Dog
Dose: 10, 1, 0.1, and 0.03 mg/kg
Route of delivery:
Oral
Plasma half life:
10 h
Systemic clearance:
0.35 mL/min/kg
Fb :
99.83%
Bioavailability:
73%
Volume of Distribution at Steady-State:
0.3 L/Kg
DOI Reference: 10.1021/acs.jmedchem.1c01012
Monkey (Cynomolgus)
Dose: 10, 1, 0.1, and 0.03 mg/kg
Route of delivery:
Oral
Plasma half life:
7.1 h
Systemic clearance:
0.84 mL/min/kg
Fb :
99.957%
Bioavailability:
122%
Volume of Distribution at Steady-State:
0.38 L/Kg
DOI Reference: 10.1021/acs.jmedchem.1c01012
Chemical Information
| Molecular Formula | C22H26N6O2 |
| SMILEs | CCc1cc2ncc(CN3CCN(c4ccc(C(=O)NC)nc4)CC3)cc2[nH]c1=O |
| InChI | InChI=1S/C22H26N6O2/c1-3-16-11-19-20(26-21(16)29)10-15(12-24-19)14-27-6-8-28(9-7-27)17-4-5-18(25-13-17)22(30)23-2/h4-5,10-13H,3,6-9,14H2,1-2H3,(H,23,30)(H,26,29) |
| Molecular weight | 406.21 Da |
| AlogP | 0.0 |
| HBond acceptors | 8 |
| HBond donors | 2 |
| Atoms | 56 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.